Intellia Therapeutics Inc  

(Public, NASDAQ:NTLA)   Watch this stock  
Find more results for NTLA
-1.64 (-6.25%)
Mar 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 24.25 - 25.79
52 week 11.15 - 35.99
Open 25.79
Vol / Avg. 2.90M/1.33M
Mkt cap 1.04B
P/E     -
Div/yield     -
EPS -1.86
Shares 42.39M
Beta     -
Inst. own 60%
Mar 20, 2018
Intellia Therapeutics Inc at Morgan Stanley Healthcare Corporate Access Day Add to calendar
Mar 13, 2018
Intellia Therapeutics Inc at Barclays Global Healthcare Conference
Feb 27, 2018
Intellia Therapeutics Inc at Credit Suisse Global Healthcare Conference
Feb 14, 2018
Intellia Therapeutics Inc at Leerink Partners Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '17) 2017
Net profit margin -359.37% -258.62%
Operating margin -370.65% -266.32%
EBITD margin - -254.83%
Return on average assets -30.74% -20.01%
Return on average equity -40.35% -26.46%
Employees 195 -
CDP Score - -


40 Erie St Ste 130
CAMBRIDGE, MA 02139-4254
United States - Map
+1-857-2856200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company's division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company's subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue.

Officers and directors

Perry A. Karsen Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
John M. Leonard M.D. President, Chief Executive Officer
Age: 59
Bio & Compensation  - Reuters
Graeme Bell Chief Financial Officer, Executive Vice President
Age: 50
Bio & Compensation  - Reuters
Jose E. Rivera J.D. Executive Vice President, General Counsel
Age: 51
Bio & Compensation  - Reuters
Frank Verwiel M.D., Director
Age: 54
Bio & Compensation  - Reuters
Caroline D. Dorsa Independent Director
Age: 57
Bio & Compensation  - Reuters
Jean-Francois Formela M.D. Independent Director
Age: 60
Bio & Compensation  - Reuters
Carl L. Gordon Ph.D. Independent Director
Age: 52
Bio & Compensation  - Reuters